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Abstract
Backgrounds: Prognostic factors are defined as biological or clinical measurement associated
with overall survival and/or disease-free survival. Previous studies have shown that patients with
estrogen receptor (ER) positive cancers have a better prognosis than patients whose cancers do
not have these receptors.
Methods: This study investigated the assessment of variables in defining prognosis of 742 breast
cancer women with pathological stage (pTNM) I-III diagnosed between 1980 and 2005 at the Kyoto
University Hospital in Japan, by age, clinical stage (cTNM), pTNM, the numbers of positive lymph
nodes (pN), and ER status.
Results: Multivariate analysis demonstrated that pTNM and ER status were the independent
prognostic factors for overall survival, and that pTNM and pN were the independent prognostic
factors for disease-free survival. For the 0- to 2-year interval, the hazard of recurrence was higher
for the ER-negative patients than the ER-positive patients, and beyond 3 years the hazard was
higher for ER-positive patients.
Conclusion:  The present study confirmed the previous reports which showed favorable
prognosis of the patients with lesser pTNM or positive ER status. A reversal of recurrence hazard
rate between ER positive and negative breast cancer patients beyond 3 years after operation was
detected. The fact may indicate the importance of long term adjuvant hormone therapy for ER
positive cancer patients.
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Background
A prognostic factor is defined as a biological or clinical
measurement that is associated with overall survival and/
or disease-free survival [1]. The knowledge of prognosis
forms an integral part of the decision-making process in
medicine [2]. Moreover, prognostic factors are important
in the treatment of cancer to help identify subgroups of
patients who may need more aggressive approach to ther-
apy [3]. Further, prognostic factors also play a critical role
in designing clinical trial as stratification and allocation
factors [4]. Prognostic factors, i.e., those that predict the
risk of recurrence or death from breast cancer, include
stage, number of positive axillary nodes, tumor size, lym-
phatic and vascular invasion, the estrogen-receptor (ER)
and progesterone-receptor (PR) positivity, and HER2/neu
gene amplification [3,5]. We previously reported that the
recent advance of the survival rates in breast cancer
patients may be due to the rational development of treat-
ment [6]. In order to assess the independent value of var-
iables in defining prognosis, in the present study, we have
investigated the survival of 742 breast cancer patients with
pathological stage (pTNM) I-III, by the age, clinical stage
(cTNM), pTNM, the numbers of positive lymph nodes
(pN) and ER status.
Methods
Patients
742 female beast cancer patients aged between 21 and 80
with stage I-III of pTNM were selected from the patients
treated at Kyoto University Hospital in Japan from 1980
to 2005. Based on the section 2 in chapter 1 of Japanese
ethical guidelines for epidemiological research
http:www.niph.go.jp/english2/english ver/ethical-gl/
guide lines.htm, this study was exempt from ethical
approval under Japanese law and guidelines. Moreover,
all treatments for breast cancer were undertaken with
informed consent and consents were also taken to con-
firm cancer diagnosis. These patients underwent surgery
with axillary lymph node dissection. The operation meth-
ods were classified into three groups: breast conserving
surgery, modified radical mastectomy, and standard radi-
cal mastectomy. All the patients with breast conserving
surgery received radiation therapy. Staging of cTNM and
pTNM was evaluated according to UICC stage [7].
Number of lymph node metastasis and ER status of the
primary tumors were analyzed by staff members of the
Department of Pathology at Kyoto University Hospital.
Using immunohistochemistry on the whole series of
tumors, they assessed estrogen receptor (ER) status in a
standardized way. In our institute, the pathologists rou-
tinelyhave examined the ER status of tumors by using the
immunohistochemistry since the 1980s. The contents of
treatments for breast cancer patients were previously
described [6]. According to the years of surgery the
patients were grouped into two cohorts: period I (1980–
1989) and period II (1990–2005). In period I, modified
radical mastectomy with lymph node dissection was
included. In this period, breast-conserving surgery was not
performed, because it was not recognized to be the pre-
vailing method in Japan. In period II, breast-conserving
surgery was the treatment of choice for women with rela-
tively small breast cancers during this past decade in
Japan. In our institute, all patients with breast-conversing
surgery received radiation therapy. In the treatment stage
I, II, IIIA, and operable stage IIIC breast cancer, breast-
conserving surgery or modified radical mastectomy with
lymph node dissection and with or without breast recon-
struction surgery was included. In the treatment of stage
IIIB and inoperable stage IIIC breast cancer, systemic
chemotherapy, or systemic chemotherapy followed by
surgery, with lymph node dissection followed by radia-
tion therapy were included. If necessary, additional sys-
temic therapy such as chemotherapy, hormone therapy,
or both were given. Moreover, if necessary, adjuvant ther-
apy such as systemic chemotherapy (per os only) with or
without hormone therapy (tamoxifen or tremifene) was
included. The patients received adjuvant chemotherapy
with LH-RH agonist after 2001, cyclophosphamide, epiru-
bicin and 5-fluorouracil (CEF) or Cyclophosphamide,
methotrexate and 5-fluouracil (CMF) regimen after 2002,
and rational developers such as taxane, trastuzumab, or
aromatase inhibitor therapy after 2004.
Statistical analysis
Disease-free survival was defined from the operation day
to the identification date of recurrence of cancer or death
from any cause, and overall survival was defined from the
operation day to death from any cause. Survival curves
were estimated with the Kaplan-Meier method. To iden-
tify prognostic factors independently associated with the
overall survival or disease-free survival and to estimate the
hazard ratios, the Cox proportional hazard model was
applied. Two-sided p <0.05 was regarded as statistically
significant. The statistical analysis was conducted with
SPSS version 11.0 statistical software.
Results
Patient Characteristics
Patient characteristics are summarized in Table 1. The
medianfollow-uptime of the investigated period in this
study was as same as the median follow-up time forsurviv-
ingpatients (5.7 years).
10-year overall survival
The 10-year overall survival rates classified by age, cTNM,
pTNM, pN, ER status and types of breast surgery are
shown in Table 2. Figure 1 shows the overall survival
curves in ER-positive and ER-negative patients.BMC Cancer 2008, 8:323 http://www.biomedcentral.com/1471-2407/8/323
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10-year disease-free survival
The 10-year disease-free survival rates classified by age,
cTNM, pTNM, pN, ER status and types of breast surgery
are shown in Table 3. The approximate 10-year disease-
free survival between ER positive and negative patients
was reversed (Figure 2). According to age, cTNM, pTNM
and pN, the reversal of disease-free survival was not
detected in the present study (Table 3).
Estrogen receptor status
Because beyond 10 years hazard had increased statistical
errors, we investigated the annual hazard of recurrence
until 10 years after operation. For the 0- to 2-year interval,
the hazard of recurrence was higher for the ER-negative
patients than the ER-positive patients, and beyond 3 years
the hazard was higher for ER-positive patients (Figure 3).
Figure 4 shows that the overall survival of ER-positive can-
cer patients was increased by adjuvant hormone therapy
(p = 0.009). Moreover, among 452 ER-positive cases, at 1
year after surgery, the hazard of recurrence was higher for
the patients with adjuvant hormone therapy than the
patients without adjuvant hormone therapy, but between
2 and 4 years, the hazard was higher for the patients with-
out adjuvant hormone therapy (Figure 5).
Prognostic factor analysis
Age (<35; 35–54; ≥ 55), cTNM (stage I-III), pTNM (stage
I-III), pN (pN0, pN1, pN2, pN3), ER status (negative, pos-
itive, unknown), and types of breast surgery (breast con-
serving surgery, modified radical mastectomy, radical
mastectomy) were analyzed as potential prognostic fac-
tors by the Cox proportional hazard model. Both univari-
ate analyses to determine prognostic factors associated
with overall survival and disease-free survival that the fea-
tures with p < 0.05 were 5 features: cTNM, pTNM, pN, ER
status, and type of surgery (Table 2 &3). The important
prognostic factor associated with overall survival deter-
mined by multivariate analyses with backward variables
selection were 2 features: pTNM and ER status (Table 4).
The important prognostic factor associated with disease-
free survival determined by multivariate analyses with
backward variables selection were two features: pTNM
and pN (Table 4).
Discussion
Tumor staging systems provide information about extent
of disease that can be used to guide treatment recommen-
dations and provide estimates of patient prognosis. It is
well known that pathological stage is the most significant
independent prognostic factor for determining survival in
breast cancer [8]. Our study documents the fact that path-
ological stage is the independent prognostic factor for
both overall survival and disease-free survival.
Many studies have shown that women with ER positive
cancers have a better prognosis than patients whose can-
cers do not have this receptor [9,10]. In this study cohort,
ER status were the independent prognostic factors for
overall survival by the multivariate Cox regression analy-
sis, but ER status did not affect disease-free survival (Table
3 &4). Nomura et al. [11] previously reported that in a ret-
rospective multicenter study to investigate the ER status in
primary breast cancer with patient prognosis, 3,118
patients with operable breast cancer (stages I-III) were
investigated from ten hospitals in Japan who underwent
surgery from October 1972 to December 1982, and that
Cox's multivariate analysis showed that overall survival,
but not disease-free survival was affected by ER status.
They speculated the possibility that this was due to the
longer postrelapse survival in patients with ER-positive
cancer based on the effectiveness of endocrine treatment.
Preceding paper has reported that the patients of positive
ER status enjoyed benefits from the recent development of
breast cancer treatments [6]. In fact, the present study
showed that the overall survival of ER-positive cancer
patients was increased by adjuvant hormone therapy (Fig-
ure 4).
Hortobagyi et al. [12] previously reported that the disease-
free survival in estrogen receptor (ER) positive and/or pro-
Table 1: Patient characteristics (n = 742)
number %
Gender
female 742 100
male 0 0
Age
<35 (21–34) 35 4.7
35–54 337 45.4
≥ 55 (55–91) 370 49.9
cTNM stage
Stage I 197 26.6
Stage II 452 60.9
Stage III 93 12.5
pTNM stage
Stage I 189 25.5
Stage II 397 53.5
Stage III 156 21.0
pN
pN0 422 56.9
pN1 189 25.5
pN2 88 11.9
pN3 43 5.8
ER status
negative 290 39.1
positive 452 60.9
Breast surgery
Breast conserving surgery 305 41.1
Modified radical mastectomy 429 57.8
Standard radical mastectomy 8 1.1BMC Cancer 2008, 8:323 http://www.biomedcentral.com/1471-2407/8/323
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gesterone receptor (PgR) positive patients was higher than
that in ER/PgR negative patients until 5 years after admin-
istration of the state-of-the-art adjuvant therapy, however,
the disease-free survivals between these groups was
reversed after 5 years. Saphner et al. [13] reported that
compared with ER negative patients, ER positive patients
had lower annual hazard of recurrence until around 3.5
years after surgery, but thereafter higher. In the present
study, Figure 3 shows that a positive ER status was associ-
ated with a lower hazard of recurrence in the first 2 years
after surgery, but a higher hazard of recurrence from years
3 to 10. [14]. Results from the EBCTCG meta-analysis of
systemic treatment of early breast cancer by hormone,
cytotoxic, or biologic therapy methods in randomized tri-
als involving 144,939 women show a highly significant
advantage of 5 years versus 1 to 2 years of tamoxifen with
respect to the risk of recurrence [14]. In the present study,
in ER-positive cases, between 2 and 4 years after surgery,
the hazard of recurrence of patients without adjuvant hor-
mone therapy was higher than the patients with adjuvant
hormone therapy (Figure 5). It is noteworthy that this
observation emphasizes the importance of adjuvant hor-
mone therapy for ER positive cancer patients beyond 3
years after operation. Moreover, comparing with the 10-
year survival rate between ER-positive patients with or
without hormone therapy and ER-negative patients (Fig-
ure 1 &4), the survival rate between ER-positive patients
without hormone therapy and ER-negative patients was
similar, but the adjuvant hormone therapy led about 13%
Table 2: The 10-year overall survival rates and univariate Cox regression analysis
Factors overall survival rates Hazard ratio Log-rank test
p-value
10-year (%) 95% CIa 95% CI a
Age
< 35 69.6 57.7–81.5 1.00 - 0.30
35–54 78.1 75.2–81.0 0.69 0.30–1.59
≥ 55 73.4 69.9–77.0 0.90 0.39–2.08
cTNM
Stage I 85.7 81.3–90.0 1.00 - <0.001
Stage II 75.8 73.1–78.5 2.32 1.31–4.09
Stage III 54.5 46.9–62.0 4.85 2.55–9.22
pTNM
Stage I 89.4 85.8–93.1 1.00 - <0.001
Stage II 81.7 79.1–84.4 2.10 1.10–4.03
Stage III 46.4 40.8–51.9 7.77 4.08–14.81
pN
pN0 86.7 84.2–89.1 1.00 - <0.001
pN1 76.4 72.1–80.7 1.74 1.08–2.82
pN2 46.6 39.7–53.4 5.25 3.34–8.27
pN3 38.2 26.9–49.5 5.34 3.01–9.47
ER status
Negative 71.0 67.7–74.3 1.00 - 0.012
Positive 79.5 76.5–82.5 0.63 0.44–0.91
Breast surgery
Breast conserving surgery 76.1 71.2–81.0 1.00 - 0.093
Modified radical mastectomy 76.2 73.7–78.7 1.31 0.84–2.04
Standard radical mastectomy 19.1 2.29–35.8 4.09 1.57–10.64
a CI: Confidence interval.
Overall survival curves in ER-positive and ER-negative  patients Figure 1
Overall survival curves in ER-positive and ER-nega-
tive patients. (Number) = number of patients. p = 0.012.
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Table 3: The 10-year disease-free survival rates and univariate Cox regression analysis
Factors disease-free survival rates Hazard ratio Log-rank test
p-value
10-year (%) 95% CI a 95% CI a
Age
< 35 47.0 33.3–60.7 1.00 - 0.49
35–54 59.0 55.7–62.4 0.91 0.50–1.64
≥ 55 63.1 59.4–66.7 0.90 0.50–1.63
cTNM
Stage I 72.4 67.3–77.6 1.00 - <0.001
Stage II 60.9 58.0–63.9 2.05 1.45–2.91
Stage III 31.5 24.8–38.2 5.03 3.36–7.52
pTNM
Stage I 81.7 77.4–85.9 1.00 - <0.001
Stage II 67.5 64.4–70.5 2.18 1.47–3.24
Stage III 17.7 13.1–22.4 7.66 5.13–11.43
pN
pN0 76.6 73.8–79.5 1.00 - <0.001
pN1 56.4 51.6–61.2 1.85 1.36–2.53
pN2 15.5 10.3–20.7 5.75 4.22–7.83
pN3 26.8 16.6–37.1 4.88 3.25–7.32
ER status
Negative 59.8 56.4–63.2 1.00 - 0.183
Positive 60.0 56.6–63.4 0.83 0.63–1.09
Breast surgery
Breast conserving surgery 59.1 54.1–64.0 1.00 - 0.007
Modified radical mastectomy 61.5 58.7–64.3 1.14 0.86–1.52
Standard radical mastectomy NDb -3 . 3 4 1 . 7 6 – 6 . 3 3
a CI: Confidence interval,b ND: not determined.
Disease-free survival curves in ER-positive and ER-negative  patients Figure 2
Disease-free survival curves in ER-positive and ER-
negative patients. (Number) = number of patients. p = 
0.18.
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survival gains. Therefore, this fact also suggests adjuvant
hormone therapy may have more important roles in the
treatment. In addition, the disease-free survival at 10 years
after surgery between ER positive and negative patients
was reversed (Figure 2). This may be related to the fact that
the percentage of number of patients who received adju-
vant hormone therapy in ER positive patients between
1980 and 1991 (11/84: 13%) was smaller to that between
1991 and 2005 (170/368: 46%), because of reasons
including poor understanding of modern treatment for
adjuvant chemotherapy, the cost for drugs, and so on. On
the other hand, the current recommendation is that adju-
vant tamoxifen be discontinued after 5 years in all patients
as current standard therapy, because there was a trend
toward a worse outcome associated with a longer duration
of treatment [15]. Further analyses may be needed to clar-
ify the optimal duration of adjuvant hormone therapy in
operated breast cancer patients.
Traditional prognostic factors, i.e., those that predict the
risk of recurrence or death from breast cancer, include
number of positive axillary nodes [3]. It has been reported
that the pN is the most important prognostic factor affect-
ing disease-free survival and overall survival in operable
breast cancer patients [2]. However, our study suggested
that pN is the independent prognostic factor for disease-
free survival, but not for overall survival. The patients with
axillary lymph node metastasis have received chemother-
apy, hormonal therapy or both. Over the past 20 years,
various systemic adjuvant therapies have been studied to
improve survival [6]. Therefore, there may be a possibility
that the other factors such as these therapies may affect the
overall survival more stronger than pN, although further
investigations are needed to clarify this matter.
The univariate Cox regression analysis for overall survival
and disease-free survival demonstrated that the hazard
ratio of patients with breast conserving surgery was lower
Overall survival curves in ER-positive patients with and with- out adjuvant hormone therapy Figure 4
Overall survival curves in ER-positive patients with 
and without adjuvant hormone therapy. (Number) = 
number of patients. p = 0.009.
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Table 4: Multivariate Cox regression analysis for overall survival 
and disease-free survival.
Factors Overall survival
Hazard ratio 95% CI a p-value
pTNM
Stage I 1.00 -
Stage II 2.05 1.07–3.94 0.03
Stage III 8.09 4.24–15.43 <0.001
ER status
Negative 1.00 -
Positive 0.57 0.40–0.82 0.002
Factors Disease-free survival
Hazard ratio 95% CI a p-value
pTNM
Stage I 1.00 -
Stage II 1.87 1.12–3.11 0.017
Stage III 3.72 1.59–8.70 0.002
pN
pN0 1.00
pN1 1.49 1.01–2.20 0.044
pN2 2.47 1.14–5.34 0.022
pN3 1.91 0.83–4.39 0.129
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than that of patients with standard radical mastectomy
(Table 2 &3). This fact suggests that breast conserving sur-
gery with radiation therapy may provide not only cos-
metic benefit but also better prognosis, although
chronological change of breast cancer treatments may
affect the survival rates.
In conclusion, the present study presented the data of the
long term survival of pathological stage I-III patients with
breast cancers at our institution. For the 0- to 2-year inter-
val, the hazard of recurrence was higher for the ER-nega-
tive patients than the ER-positive patients, and beyond 3
years the hazard was higher for ER-positive patients. Addi-
tionally, disease free survival 10 years after operation was
reversed between ER-positive and negative patients.
Therefore, the fact may indicate the importance of long
term adjuvant hormone therapy for ER positive cancer
patients.
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